VentureMed Group

 Company Summary:
  • VentureMed Group is a commercial stage medical device company developing innovative and minimally invasive devices for the treatment of peripheral artery disease (PAD)
  • FLEX, the Company’s lead technology platform, is an innovative, cost-effective device for the endovascular treatment of patients suffering from PAD and arterio-venous access complications
Transaction Overview:
  • $15 million growth financing led by a major European Venture fund and syndicated with US Venture
Significance of the Transaction:
  • Fund VentureMed’s strategic clinical plan (which includes current and future trials in the US and Europe) and key operational and research and development programs
  • Support regulatory and reimbursement initiatives for the Company’s lead technology platform, FLEX
  • Expand the company’s worldwide commercial team
Healthios Role:
  • Healthios served as exclusive financial adviser to VentureMed Group
  • This transaction highlights Healthios commitment to capital formation in emerging growth companies and our success in completing complex transaction to maximize shareholder interests